Regulatory Relief To Promote Domestic Production of Critical Medicines

What it means

Directs federal agencies to streamline regulations for domestic pharmaceutical manufacturing. The FDA must review and eliminate unnecessary requirements, while the EPA becomes the lead agency for pharmaceutical facility permitting, with increased inspections of foreign facilities.

Expected impact

• Faster approval and construction of pharmaceutical manufacturing facilities in the US
• Potentially increased domestic production of essential medicines, reducing reliance on foreign suppliers
• Greater transparency in foreign drug manufacturing through enhanced inspections and public disclosure
• Possible reduction in regulatory barriers while maintaining safety standards for pharmaceutical production
• Economic growth in domestic pharmaceutical manufacturing sector